Serum alpha-1-antitrypsin in hemodialysis patients with dialysis arthropathy
| Autor: | Capponcini C, Docci D, Bilancioni R, Delvecchio C, Feletti C, Baldrati L |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment 030232 urology & nephrology Biomedical Engineering Medicine (miscellaneous) Alpha (ethology) Bioengineering 030204 cardiovascular system & hematology Gastroenterology Biomaterials 03 medical and health sciences 0302 clinical medicine Renal Dialysis Internal medicine Arthropathy medicine Humans Dialysis Aged Aged 80 and over business.industry Incidence (epidemiology) Amyloidosis General Medicine Middle Aged medicine.disease alpha 1-Antitrypsin Female Hemodialysis Joint Diseases business |
| Zdroj: | The International journal of artificial organs. 16(3) |
| ISSN: | 0391-3988 |
| Popis: | Dialysis arthropathy is the most prominent dialysis-related amyloidosis feature. Alpha-1-antitrypsin (alpha-1-proteinase inhibitor) is the major circulating antiprotease. Twenty-three otherwise uncomplicated hemodialysis patients with well-documented dialysis arthropathy had a significantly (p < 0.05) lower serum mean concentration, 1,960 ± 410.4 mg/I of alpha-1-antitrypsin than 47 patients with no joint symptoms who had a mean concentration of 2,256.6 ± 424.5 mg/I. Decreased levels of the substance were detected in 13 (56.5%) of the 23 patients with dialysis arthropathy and in 13 (27.6%) of those 47 with no joint symptoms, the incidence in the former group being significantly (p < 0.05) higher than in the latter. In the dialysis arthropathy group, serum alpha-1-antitrypsin levels correlated inversely (r = −0.54, p < 0.01) with the dialysis duration and directly (r = 0.413, p < 0.05) with the corresponding beta-2-microglobulin determinations. We speculate that reduced antiprotease activity may play a role in amyloidogenesis in the setting of long-term hemodialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|